Table 5 Comparison between survivors and non-survivors of PAH and CTEPH groups
From: Assessing the spectrum of pulmonary hypertension identified at an Egyptian expert referral center
Parameter | PAH (n=76) | CTEPH (n=30) | ||||
|---|---|---|---|---|---|---|
Survivors | Non-survivors | p | Survivors | Non-survivors | p | |
Age | 42.4±14.3 | 40.7±12.5 | 0.81 | 40.2±9.8 | 47±20.7 | 0.46 |
6MWD | 232.9±113.6 | 131.2±123 | 0.116 | 238.5±100.5 | 141±128.4 | 0.139 |
mPAP | 54.35±14.7 | 53.75±10.6 | 0.962 | 50.1±11.39 | 50.2±13.2 | 0.951 |
mRAP | 6.9±4.6 | 12.5±6.9 | 0.73 | 8.8±5.1 | 12.2±6.3 | 0.21 |
mRVP | 38±12.4 | 40.2±11.4 | 0.739 | 30.5±19.5 | 38.6±8.6 | 0.42 |
PAWP | 8.15±2.4 | 9.7±3.5 | 0.278 | 9.2±2.9 | 5.2±3.1 | 0.054 |
SvO2% | 60.05±12.2 | 62±15.2 | 0.66 | 63.9±11.5 | 55.2±14.5 | 0.32 |
CI | 2.32±1.04 | 2.9±0.4 | 0.08 | 2.4±0.8 | 2.3±1.03 | 0.53 |
PVR | 13.7±8.2 | 7.9±2.7 | 0.199 | 8.9±5.1 | 9.9±3.06 | 0.94 |